Dupilumab is a fully human investigational monoclonal antibody delivered by subcutaneous injection that targets the alpha subunit of the interleukin 4 receptor (IL-4R alpha). By blocking IL-4R alpha, dupilumab modulates signaling of both IL-4 and IL-13, drivers of Th2 (Type 2 helper T cell) immune response. Dupilumab was created using Regeneron’s VelocImmune® gene modification technologies and is being co-developed with Sanofi. Dupilumab is currently in Phase 2b studies in atopic dermatitis, asthma and nasal polyposis.
Yung-Jue Bang, MD, PhD, Professor of Medical Oncology, Seoul National University College of Medicine; President, Biomedical Research Institute, Seoul National University Hospital discusses pembrolizumab for the treatment of advanced gastric cancer.
|Target||IL4 receptor alpha|
|Chemical and physical data|
|Molar mass||146.9 kg/mol|
Dupilumab, sold under the trade name Dupixent, is a monoclonal antibody designed for the treatment of allergic diseases such as eczema. Side effects include allergic reactions, cold sores, and inflammation of the cornea.
Mechanism of action
It binds to the alpha subunit of the interleukin-4 receptor (IL-4Rα), making it a receptor antagonist. Through blockade of IL-4Rα, dupilumab modulates signaling of both the interleukin 4 and interleukin 13 pathway. In clinical trials, patients saw decreased levels of Th2 bio-markers.
As per the FDA, dupilumab was manufactured in accordance with current cGMP. In October 2016, Regeneron posted a phase III CHRONOS trial, contrasting dupilumab with topical corticosteroids. The study showed that in conjunction with topical corticosteroids, people had a larger decrease in symptoms than steroids alone.
Phase III SOLO 1 and SOLO 2 trials were also performed, which evaluated the efficacy of dupilumab in combination with topical corticosteroids. In these trials 38% and 36% of patients respectively, met the primary efficacy goal of the trial.
Phase II trials for asthma treatment showed increased lung function for patients, showing increased levels of forced expiratory volume.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Dupilumab, American Medical Association.[dead link]
- "FDA approves new eczema drug Dupixent". FDA.
- "Sanofi - Commercial collaboration". Sanofi. Retrieved 2017-03-09.
- "Pipeline | A powerful research and development engine". www.regeneron.com. Retrieved 2017-03-09.
- Thomas, Katie (28 March 2017). "Severe Eczema Drug Is Approved by F.D.A.; Price Tag Is $37,000 a Year". The New York Times. Retrieved 30 March 2017.
- Kraft, M; Worm, M (April 2017). "Dupilumab in the treatment of moderate-to-severe atopic dermatitis". Expert review of clinical immunology. 13 (4): 301–310. doi:10.1080/1744666X.2017.1292134. PMID 28165826.
- Humbert, M; Busse, W; Hanania, NA (20 October 2017). "Controversies and opportunities in severe asthma". Current Opinion in Pulmonary Medicine. doi:10.1097/MCP.0000000000000438. PMID 29059087.
- [ Dupilumab in Persistent Asthma with Elevated Eosinophil Levels - Sally Wenzel, M.D., Linda Ford, M.D., David Pearlman, M.D., Sheldon Spector, M.D., Lawrence Sher, M.D., Franck Skobieranda, M.D., Lin Wang, Ph.D., Stephane Kirkesseli, M.D., Ross Rocklin, M.D., Brian Bock, D.O., Jennifer Hamilton, Ph.D., Jeffrey E. Ming, M.D., Ph.D., Allen Radin, M.D., Neil Stahl, Ph.D., George D. Yancopoulos, M.D., Ph.D., Neil Graham, M.D., and Gianluca Pirozzi, M.D., Ph.D.], NEJM.
- Shirley, Matt (2017-07-01). "Dupilumab: First Global Approval". Drugs. 77 (10): 1115–1121. doi:10.1007/s40265-017-0768-3. ISSN 0012-6667.
- "SEC 10-Q Filing of Regeneron". SEC.gov. 2017-06-30. Retrieved 2017-10-20.
- "Novel Biologic Dupilumab Improves Eczema Symptoms". Retrieved 30 October 2017.
- Walker, Joseph (2016-05-30). "New Eczema Treatments Could Be Available Soon". Wall Street Journal. ISSN 0099-9660. Retrieved 2016-05-31.
- "FDA Active Division Director Summary Review" (PDF). FDA. Retrieved 2017-10-25.
- Hamilton, Jennifer D.; Ungar, Benjamin; Guttman-Yassky, Emma (2015). "Drug evaluation review: dupilumab in atopic dermatitisjournal=Immunotherapy". 7 (10): 1043–1058. doi:10.2217/imt.15.69. ISSN 1750-7448. PMID 26598956.